The U.S. Food and Drug Administration (FDA) has issued an Emergency Use
Authorization (EUA) to permit the emergency use of Monoclonal Antibody
(MAB) for the treatment of mild to moderate COVID-19 in adult and pediatric
patients (12 years of age and older weighing at least 40kg) with positive
results of direct SARS-CoV-2 viral testing, and who are at high risk for
progression to severe COVID-19, including hospitalization or death.
MAB may speed your recovery time, decrease your risk for hospitalization,
and/or decrease the duration of your symptoms. It is an investigational
drug that continues to be studied, but early data suggests it is safe
and reduces the risk of being hospitalized.
The Parrish Medical Center Infusion Center is offering MAB to those who
meet the FDA EUA criteria.
MAB should be given as soon as possible after a positive SARS-CoV-2 result
of a direct SARS-CoV-2 viral test and within 10 days of symptom onset.
Please note we are unable to accept home test kit results.
Please call the Infusion Center at
(321) 268-6730 for more information and to determine if you qualify for MAB.
MAB is provided in an outpatient setting and is by appointment only. This
is not administered in the Emergency Department or available to walk ups.
For more information about MAB, how it can help treat COVID-19, eligibility
requirements and where to receive this treatment, please visit
parrishhealthcare.com/MABinfo.
.png)
